Navigation Links
Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Date:2/14/2012

TARRYTOWN, N.Y., Feb. 13, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012.  The presentation is scheduled for 9:00 a.m. Eastern Time.  The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentation will be available for 30 days. 

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.  A regulatory application has also been submitted to FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, with ZALTRAP® in a second indication, and with product candidate Sarilumab.  Earlier-stage clinical programs are underway with nine additional product candidates.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:   

 Manisha Narasimhan, Ph.D.Peter DworkinInvestor RelationsCorporate Communications914-847-512914.847.764manisha.narasimhan@regeneron.competer.dworkin@regeneron.com


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
2. Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
3. Regenerons Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
4. Regeneron Announces Presentation at the 2010 Deutsche Bank BioFest
5. Regeneron Announces Presentation at the 29th Annual J.P. Morgan Healthcare Conference
6. Regeneron Announces Review of Biologics License Application for EYLEAâ„¢ (aflibercept injection) Extended by Three Months by FDA
7. Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and Secretary
8. Regeneron Pharmaceuticals Announces Proposed Offering of Convertible Senior Notes due 2016
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... , ... FireflySci Inc. is a go-getter type of company that continues to ... two main factors. The first is the amazing customer service that the FireflySci ... all around the world. , 2016 was a tremendous sales year for FFS and ...
(Date:1/19/2017)... , Jan. 18, 2017 BD (Becton, Dickinson and ... announced today that it will host a live webcast of its ... p.m. (ET). The webcast can be accessed from ... for replay through Tuesday, January 31, 2017. ... About BD BD is a ...
(Date:1/18/2017)... --  Parent Project Muscular Dystrophy (PPMD) , a nonprofit ... dystrophy (Duchenne) , today announced a $600,000 grant to ... (NJIT) and Talem Technologies (Talem) as part of the ... assist people living with Duchenne. PPMD is funding a ... computer, software, a force sensor and a motor – ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical technology ... a 510(k) to the FDA, requesting clearance of the MyoCycle Home and the ... technology. , The submission marks a major milestone for the technology startup. ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
(Date:12/15/2016)... 2016  There is much more to innovative access ... engine. Continental will demonstrate the intelligence of today,s solutions ... . Through the combination of the keyless entry and ... elements, the international technology company is opening up new ... "The integration of biometric elements brings our ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition ... Service, Application Area, End User, And Region - Global Forecast to 2021", published ... in 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):